Holen Sie sich die Stockscreener-App
24.66
1.65%
0.40
Handel nachbörslich:
24.66
Schlusskurs vom Vortag:
$24.26
Offen:
$24.19
24-Stunden-Volumen:
348.97K
Relative Volume:
1.02
Marktkapitalisierung:
$793.76M
Einnahmen:
$4.85M
Nettoeinkommen (Verlust:
$-114.75M
KGV:
-7.5877
EPS:
-3.25
Netto-Cashflow:
$-100.36M
1W Leistung:
-0.60%
1M Leistung:
+14.70%
6M Leistung:
+24.17%
1J Leistung:
-11.45%
1-Tages-Spanne:
$23.70
$24.71
1-Wochen-Bereich:
$22.81
$25.22
52-Wochen-Spanne:
$13.37
$32.27
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
Firmenname
Dianthus Therapeutics Inc
Sektor
Branche
Telefon
929-999-4055
Adresse
7 TIMES SQUARE, NEW YORK
Vergleichen Sie DNTH mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DNTH
Dianthus Therapeutics Inc
|
24.66 | 767.69M | 4.85M | -114.75M | -100.36M | -3.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-02 | Eingeleitet | William Blair | Outperform |
| 2024-12-20 | Eingeleitet | TD Cowen | Buy |
| 2024-10-03 | Eingeleitet | Oppenheimer | Outperform |
| 2024-07-26 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-06-27 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-05-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-02-15 | Eingeleitet | Stifel | Buy |
| 2023-12-26 | Eingeleitet | Jefferies | Buy |
| 2023-11-22 | Eingeleitet | Wedbush | Outperform |
| 2023-10-30 | Eingeleitet | Guggenheim | Buy |
| 2023-09-28 | Eingeleitet | Raymond James | Outperform |
| 2022-08-25 | Herabstufung | Goldman | Buy → Neutral |
| 2022-01-06 | Hochstufung | Goldman | Neutral → Buy |
| 2021-08-20 | Fortgesetzt | Goldman | Neutral |
| 2021-08-03 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-07-22 | Bestätigt | B. Riley Securities | Buy |
| 2021-06-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-05-18 | Eingeleitet | B. Riley Securities | Buy |
| 2021-01-07 | Eingeleitet | Mizuho | Buy |
| 2020-06-08 | Hochstufung | Goldman | Neutral → Buy |
| 2019-03-25 | Herabstufung | Goldman | Buy → Neutral |
| 2019-03-15 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Dianthus Therapeutics Inc Aktie (DNTH) Neueste Nachrichten
Is it too late to sell Dianthus Therapeutics Inc.Market Weekly Review & Safe Entry Momentum Tips - Newser
Nuveen LLC Invests $1.17 Million in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Best data tools to analyze Dianthus Therapeutics Inc. stockProfit Target & AI Forecast for Swing Trade Picks - Newser
Vestal Point Capital LP Has $30.84 Million Stock Holdings in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
RA Capital Management L.P. Acquires 1,000,333 Shares of Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Published on: 2025-09-04 04:01:28 - Newser
Visual trend scoring systems applied to Dianthus Therapeutics Inc.Wall Street Watch & Low Drawdown Trading Strategies - Newser
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Average Rating of "Buy" by Analysts - MarketBeat
Volatility clustering patterns for Dianthus Therapeutics Inc.July 2025 Volume & Real-Time Stock Price Movement Reports - Newser
Applying Elliott Wave Theory to Dianthus Therapeutics Inc.Quarterly Earnings Report & Weekly Sector Rotation Insights - Newser
Is Dianthus Therapeutics Inc. trending in predictive chart modelsMarket Risk Analysis & High Return Stock Watch Alerts - Newser
Dianthus Therapeutics Inc. stock trendline breakdownWatch List & Daily Market Momentum Tracking - Newser
Using fundamentals and technicals on Dianthus Therapeutics Inc.Market Rally & Advanced Technical Signal Analysis - Newser
What’s the MACD signal for Dianthus Therapeutics Inc.2025 Risk Factors & Verified Momentum Stock Alerts - khodrobank.com
Backtesting results for Dianthus Therapeutics Inc. trading strategiesQuarterly Portfolio Report & Long-Term Growth Portfolio Plans - Newser
Walleye Capital LLC Increases Holdings in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Relative strength of Dianthus Therapeutics Inc. in sector analysisPortfolio Risk Report & Growth Focused Stock Pick Reports - Newser
Elliott Wave Theory Predicts Pullback in Dianthus Therapeutics Inc.Weekly Profit Summary & AI Powered Trade Plan Recommendations - Newser
What data driven models say about Dianthus Therapeutics Inc.’s futureTrade Volume Report & Consistent Profit Focused Trading Strategies - Newser
Is Dianthus Therapeutics Inc. stock showing strong momentumWeekly Gains Report & Risk Managed Investment Signals - khodrobank.com
What momentum shifts mean for Dianthus Therapeutics Inc.2025 Winners & Losers & Technical Entry and Exit Tips - Newser
Can a trend reversal in Dianthus Therapeutics Inc. lead to recovery2025 Momentum Check & Real-Time Market Trend Scan - Newser
Braidwell LP Reduces Stake in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
How to build a dashboard for Dianthus Therapeutics Inc. stockEarnings Recap Summary & Weekly High Return Stock Opportunities - Newser
Combining machine learning predictions for Dianthus Therapeutics Inc.Price Action & Weekly Market Pulse Alerts - Newser
Can swing trading help recover from Dianthus Therapeutics Inc. lossesJuly 2025 Highlights & Consistent Growth Stock Picks - Newser
Heatmap analysis for Dianthus Therapeutics Inc. and competitorsJuly 2025 Movers & Real-Time Volume Analysis - Newser
Using R and stats models for Dianthus Therapeutics Inc. forecastingQuarterly Performance Summary & High Yield Equity Trading Tips - Newser
Does Dianthus Therapeutics Inc. fit your quant trading modelJuly 2025 Movers & Verified Chart Pattern Trade Signals - Newser
Will Dianthus Therapeutics Inc. stock go up soonJuly 2025 Institutional & Free Weekly Chart Analysis and Trade Guides - Newser
Applying big data sentiment scoring on Dianthus Therapeutics Inc.Trend Reversal & Stepwise Swing Trade Plans - Newser
Technical signs of recovery in Dianthus Therapeutics Inc.Dividend Hike & AI Optimized Trading Strategy Guides - Newser
What analysts say about Dianthus Therapeutics Inc. stock2025 Sector Review & Technical Pattern Based Signals - khodrobank.com
What is Dianthus Therapeutics Inc.’s book value per shareWeekly Stock Summary & Proven Capital Preservation Tips - khodrobank.com
Is Dianthus Therapeutics Inc. in accumulation or distribution phaseMarket Performance Report & Risk Controlled Stock Pick Alerts - khodrobank.com
What’s the fair value of Dianthus Therapeutics Inc. stockJuly 2025 Chart Watch & Verified Momentum Stock Watchlist - khodrobank.com
Is Dianthus Therapeutics Inc. in a bullish channelTrade Risk Assessment & Stepwise Entry/Exit Trade Alerts - khodrobank.com
Can Dianthus Therapeutics Inc. rally from current levelsWeekly Trend Summary & AI Forecasted Stock Moves - Newser
Analyzing Dianthus Therapeutics Inc. with multi timeframe charts2025 AllTime Highs & Safe Capital Growth Trade Ideas - Newser
Does Dianthus Therapeutics Inc. stock benefit from AI growthM&A Rumor & Accurate Intraday Trading Signals - khodrobank.com
Wellington Management Group LLP Buys 7,645 Shares of Dianthus Therapeutics, Inc. $DNTH - Defense World
Understanding Dianthus Therapeutics Inc.’s price movement2025 Institutional Moves & Fast Momentum Stock Entry Tips - Newser
Analyzing net buyer seller activity in Dianthus Therapeutics Inc.Trade Signal Summary & Short-Term High Return Strategies - Newser
Momentum divergence signals in Dianthus Therapeutics Inc. chartTrade Volume Summary & Precise Buy Zone Identification - Newser
Visualizing Dianthus Therapeutics Inc. stock with heatmapsWeekly Trade Analysis & Fast Exit and Entry Strategy Plans - Newser
Finanzdaten der Dianthus Therapeutics Inc-Aktie (DNTH)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.75%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):